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T helper 17 (Th17) cells produce interleukin-17 (IL-17) cytokines
and drive inflammatory responses in autoimmune diseases such as
multiple sclerosis. The differentiation of Th17 cells is dependent on
the retinoic acid receptor-related orphan nuclear receptor RORγt.
Here, we identify REV-ERBα (encoded by Nr1d1), a member of the
nuclear hormone receptor family, as a transcriptional repressor
that antagonizes RORγt function in Th17 cells. REV-ERBα binds to
ROR response elements (RORE) in Th17 cells and inhibits the
expression of RORγt-dependent genes including Il17a and Il17f.
Furthermore, elevated REV-ERBα expression or treatment with a
synthetic REV-ERB agonist significantly delays the onset and impedes
the progression of experimental autoimmune encephalomyelitis
(EAE). These results suggest that modulating REV-ERBα activity may
be used to manipulate Th17 cells in autoimmune diseases.
transcriptional repressor | autoimmunity | nuclear receptors
Thelper 17 (Th17) cells are the drivers of inflammatory re-sponses in a large number of autoimmune diseases such as
multiple sclerosis, rheumatoid arthritis, and psoriasis (1, 2). The
orphan nuclear receptor RORγt is the lineage-specific tran-
scription factor that regulates the differentiation of Th17 cells
(3). RORγt expression is induced specifically under Th17 dif-
ferentiation condition. Once expressed, RORγt in turn binds to
the loci of Th17 signature genes Il17a and Il17f and up-regulates
their expression (4). Several small-molecule RORγt antagonists
were identified that can inhibit Th17 cell differentiation and
effector function (5–8). These findings suggested that RORγt
inhibitors could be developed for treatment of autoimmune
diseases. However, RORγt is also known for its critical role in
promoting survival of CD4+CD8+ double-positive (DP) thymo-
cytes. A recent study showed that RORγt inhibitor treatment
leads to not only reduced DP thymocyte numbers but also lim-
ited T cell repertoire diversity (9). Therefore, it is still a chal-
lenge to develop a safe strategy to inhibit RORγt activity in Th17
cells in vivo.
Beyond their critical roles in Th17 cell differentiation, members
of the ROR family are known to be key players in the circadian
regulatory machinery, where they function as transcriptional ac-
tivators to turn on the expression of circadian genes (10, 11). In
the circadian system, RORs’ transcriptional activity is opposed by
a pair of repressors, REV-ERBα and REV-ERBβ. Like RORs,
REV-ERBs are also members of the nuclear hormone receptor
family and play critical roles in circadian and metabolic regula-
tions (12). REV-ERBs recognize the same RORE DNA sequence
as RORs and function as transcriptional repressors to suppress the
expression of ROR target genes (13, 14). Although the antagonistic
relationship between ROR and REV-ERB was well established in
the circadian rhythm system, it is not clear if a similar interaction
exists in the T cell lineage.
In this study, we show that REV-ERBα is also a key feedback
regulator of RORγt in Th17 cells. REV-ERBα is specifically up-
regulated during Th17 differentiation and plays a dual role in
Th17 cells. When expressed at a low level, REV-ERBα promotes
RORγt expression via the suppression of negative regulator
NFIL3 as reported previously (15, 16). At high expression level,
REV-ERBα directly competes with RORγt binding to the loci of
Th17 signature genes and suppresses Th17 effector function. Ele-
vated REV-ERBα activity also ameliorates Th17-driven autoim-
mune disease experimental autoimmune encephalomyelitis (EAE).
Our results suggest that modulating REV-ERBα activity could
provide a way to manipulate Th17 cells in autoimmune diseases.
Results
REV-ERBα Is Highly Expressed during Th17 Cell Differentiation. In an
effort to identify novel players in the nuclear hormone receptor
superfamily that are involved in T cell function, we conducted ex-
pression profiling of nuclear hormone receptors in different T
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KEGG Pathway Term Count P value
T cell receptor signaling pathway 27 7.38E-07
Jak-STAT signaling pathway 28 3.29E-05
Chemokine signaling pathway 26 0.00334












































































































































































































































































































































































































































Fig. 1. REV-ERBα is up-regulated in Th17 cells and inhibits the expression of Th17 signature genes. (A) mRNA expression of REV-ERBα, REV-ERBβ, as well as
T cell lineage specifying transcription factors T-bet, Gata3, RORγt, and Foxp3, in naïve T cells and Th0, Th1, Th2, Th17, and iTreg cells differentiated for
3 d in vitro. (B) REV-ERBα and RORγt mRNA expression in Th1, Th17, and iTreg cells over 4 d of in vitro differentiation. (C) Protein expression of REV-ERBα, REV-
ERBβ, RORγt, and T-bet during in vitro differentiation of Th1 and Th17 cells over 4 d. (D) mRNA expression of RORγt, T-bet, and REV-ERBα in human CD4+
T cells activated under Th1 and Th17 polarizing conditions for 6 d. (E) FACS analysis of IL-17A and IFN-γ expression in mouse CD4+ T cells activated under Th1
and Th17 polarizing conditions and transduced with MIGR1, REV-ERBα or REV-ERBβ retroviral vectors. Data are representative of 3 independent experiments
with triplicate wells for each condition. (F) KEGG pathway analysis of genes differentially expressed in REV-ERBα and MIGR1 retrovirally transduced Th17 cells.
(G) Heat map of functional groups of differentially expressed genes in Th17 cells transduced with MIGR1, REV-ERBα, or REV-ERBβ retroviral vectors. Relative
fold change was normalized to the average of each row in the matrix. Data represents mean ± SEM. Statistical analyses were performed using unpaired
2-tailed Student’s t test (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001).

































KEGG Pathway Term Count P Value
T cell receptor signaling pathway 32 4.15E-08
Cytokine-cytokine receptor
interaction 50 7.76E-08
Jak-STAT signaling pathway 34 1.87E-06
MAPK signaling pathway 47 1.35E-05
Wnt signaling pathway 27 9.61E-04
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Fig. 2. REV-ERBα directly competes with RORγt and represses Th17 signature gene expression. (A) Luciferase assays of EL4 T cells cotransfected with an Il17a
luciferase reporter, and combinations of RORγt and REV-ERBα at various ratios, with the amount of RORγt transfected remaining constant. Renilla luciferase
activity was used as internal control. (B) Western blot to detect the binding of HA-tagged RORγt and Flag-tagged REV-ERBα expressed in CD4 T cells to
biotinylated oligonucleotides containing RORE motif derived from the Il17a CNS5 enhancer. (C) ChIP-qPCR to detect the binding of Il17a CNS5 enhancer, Cry1
(positive control) and Gmpr (negative control) by REV-ERBα and RORγt in Th17 cells. (D–G) Analysis of Th17 cell REV-ERBα ChIP-seq data along with published
RORγt ChIP-seq data. (D) Alignment of de novo generated REV-ERBα binding sequence to annotated RORγt binding sequence. (E) Venn diagram depicting the
numbers of unique and shared genes bound by REV-ERBα and RORγt. (F) KEGG pathway analysis of REV-ERBα bound genes. (G) Trace analysis of ChIP-seq data
visualized on the UCSC genome browser showing overlapping binding sites of REV-ERBα and RORγt at Il17a and Il17f loci. (H and I) ChIP-qPCR to detect
changes in REV-ERBα and RORγt binding to the Il17a locus in response to ectopic expression of REV-ERBα (H) or RORγt (I). Data represents mean ± SEM.
Statistical analyses were performed using unpaired 2-tailed Student’s t test (*P < 0.05, **P < 0.01, ***P < 0.001).
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helper cell subsets. We noticed that, similar to RORγt, REV-ERBα
expression was uniquely up-regulated in Th17 cells at both mRNA
and protein levels (Fig. 1 A–C). The differences in the kinetics of
REV-ERBα mRNA and protein expression are likely due to a
tightly regulated protein degradation pathway of REV-ERBα (17,
18). Furthermore, REV-ERBα expression was significantly higher
in human Th17 cells relative to Th1 cells (Fig. 1D). The unique
expression pattern of REV-ERBα suggested that it may play a role
in the regulation of Th17 cells. Previous studies on circadian reg-
ulation demonstrated that, by binding to the same RORE motifs,
RORs activate transcription of their target genes, whereas REV-
ERBs act as repressors of the same targets (13, 14). We hypothe-
sized that REV-ERBs may suppress Th17 cell differentiation and
function by antagonizing RORγt.
Ectopic Expression of REV-ERBα Inhibits the Expression of Th17
Signature Genes. To assess the role of REV-ERBs in Th17
cells, we examined the effects of ectopic expression of REV-
ERBs on Th1 and Th17 cell differentiation. Retroviral expres-
sion of REV-ERBα during Th17 differentiation significantly
suppressed interleukin-17A (IL-17A) production compared to
T cells transduced with control vector MIGR1 (Fig. 1E). The
inhibitory effect of REV-ERBα is specific to Th17 cells, as it did
not suppress interferon (IFN)-γ expression in Th1 cells. Ectopic
expression of REV-ERBβ showed a modest negative impact on
Th17 cells (Fig. 1E). Th17 differentiation can also be driven
by ectopic expression of RORγt in T cells cultured without
Th17 polarizing cytokines (3). We found that coexpression of
REV-ERBα along with RORγt also led to significant decrease
of IL-17A expression (SI Appendix, Fig. S1), suggesting that
REV-ERBα can suppress RORγt-dependent IL-17A expres-
sion. To evaluate the genome-wide effects of REV-ERBs’ ec-
topic expression in Th17 cells, we performed RNA-sequencing
(RNA-seq) analysis of Th17 cells retrovirally transduced with
REV-ERBα, REV-ERBβ, or MIGR1 control vector (19). KEGG
pathway analysis of the differentially expressed genes indicated
that REV-ERBα regulates genes involved in T cell receptor
signaling, cytokine/chemokine signaling, as well as circadian
rhythm regulation (Fig. 1F). REV-ERBα–transduced cells dif-
ferentially expressed a number of Th17 cell signature genes
compared with MIGR1-transduced cells, which include Il17a,
Il17f, Il23r, Csf2, and Tgfb3. Interestingly, most of these genes
were significantly down-regulated by REV-ERBα (Fig. 1G).
REV-ERBβ expression also suppressed most Th17 signature
genes, but its impact was modest compared to REV-ERBα (Fig.
1G). Therefore, we decided to focus on the role of REV-ERBα
in suppressing Th17 cell differentiation and the expression of
Th17 signature genes.
REV-ERBα Directly Competes with RORγt and Represses Th17 Signature
Gene Expression. Since REV-ERBs and RORs both recognize
ROREs, we hypothesized that REV-ERBα could directly interact
with the Il17a locus and repress its transcription. RORE motifs
located in CNS5 (also named CNS2), an enhancer 5 kb upstream
of the Il17a locus, are critical for optimal expression of Il17a (20–
22). Using a reporter driven by the Il17a promoter and CNS5
(20), we measured luciferase activity after transfecting RORγt
with or without REV-ERBα. Cotransfection of REV-ERBα
inhibited RORγt-dependent Il17a reporter activity in a dose-
dependent manner (Fig. 2A). To investigate whether REV-
ERBα can directly bind to ROREs located at the Il17a locus,
we performed an in vitro DNA binding assay. Biotinylated oli-
gonucleotides containing the RORE motif derived from the
Il17a CNS5 enhancer were incubated with nuclear extracts from
mouse CD4 T cells transduced with either REV-ERBα− or
RORγt-expressing retroviral vectors. The DNA:protein com-
plexes were then precipitated with streptavidin beads, and
Western blots were performed to detect precipitated REV-
ERBα and RORγt. As shown in Fig. 2B, both REV-ERBα and
RORγt bind to the RORE motif. To determine if the REV-
ERBα:CNS5 interaction occurs in vivo, we performed chromatin
immunoprecipitation (ChIP) experiments in Th17 cells with anti-
REV-ERBα and anti-RORγt antibodies. Indeed, both REV-
ERBα and RORγt bound to the CNS5 region in Th17 cells
(Fig. 2C). These findings suggest that REV-ERBα can directly
repress Il17a expression by binding to the Il17a CNS5 enhancer.
To identify genome-wide REV-ERBα target genes in Th17
cells, we performed REV-ERBα ChIP-seq assays (23). As
expected, the de novo REV-ERBα binding motif is highly similar
to the established RORγt binding motif (Fig. 2D). When com-
pared to previously published RORγt ChIP-seq data, about 30%
of the 8,884 REV-ERBα binding sites in Th17 cells are also
RORγt binding sites (Fig. 2E) (4). It is expected that a large
proportion of REV-ERBα binding peaks are different from
RORγt binding peaks despite their shared binding motif. This is
partly due to the finding that REV-ERBα can target DNA in-
directly by interacting with other transcription factors (24).
KEGG pathway analysis of genes bound by both REV-ERBα
and RORγt revealed that they are enriched with genes in-
volved in T cell signal and cytokine/chemokine pathways (Fig.
2F). In addition to Il17a, several other Th17 cell signature genes,
including Il17f, Il23r, and Tgfb3, were also identified as direct
targets of REV-ERBα (Fig. 2 E and G and SI Appendix, Fig. S2).
The finding that REV-ERBα binds to a large number of RORγt
target genes suggests that REV-ERBα inhibits Th17 cell differ-
entiation through direct suppression of the expression of key
Th17 cell signature genes. To further test this hypothesis, we
examined whether ectopic REV-ERBα expression decreases the
binding of RORγt to Il17a by ChIP-qPCR. Indeed, RORγt
binding at the Il17a locus decreased significantly in cells trans-
duced with a REV-ERBα expressing retroviral vector (Fig. 2H).
Conversely, ectopic expression of RORγt diminished REV-
ERBα binding at the Il17a locus (Fig. 2I).
In Vivo Induction of REV-ERBα Expression in T Cells Suppresses EAE
Disease Progression. Since high levels of REV-ERBα expression
are inhibitory to Th17 cell differentiation in vitro, we explored
whether constitutive REV-ERBα expression in T cells could
ameliorate Th17 cell-mediated autoimmune diseases in vivo. We
tested this hypothesis in EAE, a mouse model for multiple scle-
rosis, as Th17 cells play a critical role in EAE disease develop-
ment. A tetracycline-inducible REV-ERBα transgenic mouse
(TRE-REV-ERBα/Rosa-M2rtTA) (25) was crossed with a 2D2
TCR transgenic mouse, which carries a TCR that recognizes the
MOG (myelin oligodendrocyte glycoprotein) peptide (26), to
generate a triple transgenic mouse strain (TTg). T cells from the
TTg mice express REV-ERBα constitutively under doxycycline
treatment in vivo (SI Appendix, Fig. S3A). CD4+ T cells from the
TTg mice were activated in vitro under Th17 conditions for 4 d
before being adoptively transferred into WT recipient mice to
induce EAE. Mice were given doxycycline water to induce REV-
ERBα expression in transferred 2D2 T cells or normal water. The
doxycycline-treated group showed delayed EAE disease onset as
well as slower disease progression compared to mice that were
given normal water (Fig. 3A). Elevated REV-ERBα expression
did not affect homing, proliferation, or survival of the transferred
CD4+ T cells (SI Appendix, Fig. S3B). However, consistent with
milder disease progression observed in mice treated with doxycy-
cline, the frequency of IL-17A producing 2D2 T cells were sig-
nificantly reduced in the CNS tissues of these mice compared to
controls (Fig. 3B). Histopathology analysis showed that doxycy-
cline treatment significantly reduced inflammation levels with a
decreasing trend for demyelination in the spinal cord of these
mice (Fig. 3 C and D). These differences were dependent on
REV-ERBα induction because the same doxycycline treatment of
mice transferred with WT 2D2 T cells did not delay or ameliorate





















EAE disease progression (SI Appendix, Fig. S3C). Thus, elevated
expression of REV-ERBα in T cells can attenuate Th17 cell-
mediated EAE.
REV-ERBα Deficiency Impairs Th17 Cell Differentiation. Despite the
suppressive role of REV-ERBα on the expression of Th17 sig-
nature genes, a previous study by Hooper and coworkers (15)
showed that REV-ERBα–deficient T cells were also defective in
Th17 differentiation. It was proposed that in the absence of
REV-ERBα, expression of NFIL3 increases, which, in turn,
suppresses Th17 cell development by directly binding to the
RORγt promoter and repressing its expression. We assessed the
effect of REV-ERB ablation in Th17 cell differentiation and
function. The REV-ERBα/β knockout T cells showed a moder-
ate reduction in Th17 differentiation measured by IL-17A ex-
pression (Fig. 4A), consistent with the findings by Hooper’s
group. To test the impact of REV-ERB deletion in vivo, we
utilized T cell-specific REV-ERBα/β conditional knockout mice
(REV-ERBαfl/fl/βfl/fl CD4Cre) (14). The REV-ERB conditional
knockout mice and WT controls were immunized with MOG/
CFA to induce EAE. Disease development was monitored for 3
wk and followed by analysis of T cell composition in CNS tissues.
Mice carrying REV-ERB null T cells developed milder EAE
accompanied with reduced IL-17A–producing T cells in the CNS
tissues (Fig. 4 B and C). These results suggest that REV-ERBα
expression needs to be tightly regulated for robust Th17 cell
differentiation. Insufficient REV-ERBα activity leads to de-
creased Th17 cell differentiation due to increased levels of
NFIL3, which suppress RORγt expression, whereas at high levels
REV-ERBα outcompetes RORγt for regulatory binding sites in
Th17 signature genes such as Il17a and Il17f, also resulting in the
suppression of Th17 cell differentiation. It is worth noting that
overexpression of REV-ERBα exerts a much stronger inhibitory
effect on Th17 cells than absence of REV-ERBα expression
(Figs. 1E and 4A).
A Synthetic Agonist of REV-ERBα Can Inhibit Th17 Cell Differentiation
In Vitro and Ameliorate EAE In Vivo. Structural studies have shown
that REV-ERBs contain a ligand binding domain, and their
activity can be modulated by specific ligands (27). Heme, the
prosthetic group in hemoglobin, was identified as an endogenous
agonist that binds to REV-ERBs and potentiates their activity
(28, 29). Efforts have also been made to generate synthetic REV-
ERB agonists with higher specificity and fewer side effects. Two
chemical compounds, SR9009 and SR9011, bind specifically to
REV-ERBs and modulate their activity, and exhibited favorable
pharmacokinetic properties when tested in mice (30–32). Since
increased REV-ERBα expression suppresses Th17 cell differ-
entiation and function, we tested if potentiating REV-ERB ac-
tivity via agonist treatment could have a similar effect on Th17
cells. First, we cultured naïve mouse CD4 T cells under Th1, Th17,
or iTreg differentiation conditions with or without SR9009.
SR9009 treatment significantly inhibited Th17 cell differentiation
but did not affect Th1 or iTreg differentiation (Fig. 5 A and B).
Similarly, Th17, but not Th1, differentiation of human CD4 T cells
was significantly inhibited by SR9009 treatment (Fig. 5C). To test
the specificity of SR9009, we cultured CD4 T cells isolated from
REV-ERBα/β conditional knockout and WT control mice under
Th17 differentiation condition with or without SR9009 and mea-
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Fig. 3. In vivo induction of REV-ERBα expression in Th17 cells suppresses EAE disease progression. EAE was induced in C57/BL6 mice by adoptive transfer of
in vitro differentiated Rosa-M2rtTAxTRE-REV-ERBax2D2 transgenic Th17 cells. Recipient mice were treated with or without Doxycycline water (n = 7 per
group) starting 2 d before Th17 cell adoptive transfer and were monitored for EAE disease progression. Mice were analyzed on day 24 after transfer. (A)
Clinical scores of mice induced with EAE. (B) FACS analysis of IL-17A and IFN-γ production of transferred 2D2 CD4+ T cells infiltrating in the CNS tissues. (C)
Representative H&E and Luxol Fast Blue staining of the spinal cords to show the sites of immune cell infiltration (filled arrow) and demyelination (open
arrow). Data represents mean ± SEM. Statistical analyses were performed using 2-way analysis of variance (ANOVA) for EAE clinical score analysis and 2-tailed
unpaired Student’s t test for other analysis, comparing the indicated groups (*P < 0.05, **P < 0.01).
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T cells was suppressed by SR9009 treatment, IL-17A expression in
REV-ERB null T cells was not affected (Fig. 5 D and E). These
results suggest that SR9009 can inhibit Th17 differentiation by
modulating REV-ERB activity.
To investigate the molecular mechanism of SR9009’s effect in
Th17 cells, we examined the recruitment of NCoR, a corepressor
that binds to REV-ERB and represses its target gene expression
(24). ChIP-qPCR assay showed that NCoR recruitment to the
Il17a CNS5 enhancer increased significantly in the presence of
SR9009, indicating that SR9009 can target the IL17A pathway
directly via enhancing NCoR:REV-ERB interaction at the Il17a
locus (Fig. 5F).
The inhibitory effect of SR9009 on Th17 differentiation in vitro
compelled us to test if it could also exert similar modulating effect
on Th17-induced autoimmune diseases in vivo. Unlike RORγt
antagonists, SR9009 treatment did not skew T cell development in
the thymus or grossly affect T cell activation state in the periphery
(SI Appendix, Fig. S4).
To test the effect of SR9009 treatment in mouse EAE models,
we immunized C57/BL6 mice with MOG/CFA and started in-
jection of SR9009 or vehicle control 7 d after initial immunization.
Mice treated with SR9009 showed significantly delayed onset and
slower progression of EAE compared to vehicle-treated control
group (Fig. 5G). SR9009 treatment also reduced the frequency of
IL-17A–producing CD4 T cells infiltrating the CNS tissues during
EAE (Fig. 5H). We next explored the efficacy of REV-ERB ag-
onist treatment on mice that have already developed EAE. We
induced EAE in SJL mice, which upon PLP (myelin proteolipid
protein) peptide immunization, exhibit disease progression in re-
mitting and relapsing patterns mimicking the development of
multiple sclerosis in humans. SR9009 treatment of SJL mice
during the primary phase of EAE showed inhibitory effects similar
to its effects in C57/BL6 mice (data not shown). When SR9009
was administered in the remitting phase, SR9009-treated mice
maintained their remitting state, whereas vehicle-treated control
mice developed additional episodes of EAE symptoms (Fig. 5I).
Furthermore, the frequency of IL-17A–producing CD4 T cells was
also significantly reduced in the CNS tissues of SR9009-treated
mice compared to controls (Fig. 5J). These results demonstrate
that modulating in vivo REV-ERB activity by its agonist SR9009
effectively suppresses development and progression of Th17 cell-
mediated EAE.
Discussion
In this study, we demonstrated a role for REV-ERBα in the
regulation of Th17 cell differentiation and function in addition to
its established roles in circadian rhythm and metabolism. REV-
ERBα is induced during Th17 cell differentiation and directly
competes with RORγt by binding to the RORE sites to repress the
expression of key Th17 cell signature genes such as Il17a and Il17f.
At the same time, normal RORγt induction is also dependent on
repression of Nfil3 by REV-ERBα (15). This is substantiated by
reduction of IL-17A production in vitro and milder EAE pheno-
type in vivo as a result of T cell-specific REV-ERB ablation. These
observations suggest that REV-ERBα serves as a feedback regu-
lator for RORγt in T cells, and its expression needs to stay at the
right level for optimal Th17 differentiation.
A recent study by Amir et al. reported similar results showing
reduced Th17 activity when REV-ERB expression is increased
(33). However, the same study also showed Th17 differentiation
was enhanced in REV-ERBα knockout T cells, which differs
from our results and the study performed by Yu et al. (15). One
primary difference between the 2 studies is that T cell-specific
REV-ERB conditional knockout mice were used in our study,
while REV-ERBα germline knockout mice were used in the study
by Amir et al. Since REV-ERBα germline knockout mice carried
severe defects in circadian and metabolic regulation, it is possible
that these perturbations originated outside of the immune system
rendered T cells more inflammatory under Th17-inducing condi-
tions. Additionally, differences in gut microbiota between mouse
facilities might also contribute to the contradictory results.
Given the key role REV-ERBα plays in Th17 cells, we ex-
plored if tuning REV-ERBα activity can influence Th17 differ-
entiation and function. Our results showed that elevated REV-
ERBα expression in T cells or treatment with REV-ERB ligand
SR9009 suppresses Th17 cell differentiation in vitro and inhibits
the development of EAE in vivo. Although specific REV-ERBα
induction in T cells is sufficient to ameliorate EAE, SR9009
treatment in mice might also impact non-Th17 cells. A previous
study demonstrated that REV-ERBα could suppress macro-
phage expression of IL-6, a key cytokine for Th17 cell differen-
tiation (34). We also observed that subsets of gamma/delta
T cells and regulatory T cells could express high levels of REV-
ERBα, although the significance of these cell subsets in EAE
pathogenesis is currently unclear and requires further charac-
terization. A recent study raised concern on the specificity of
SR9009 by demonstrating that SR9009 could exert REV-ERB
independent effects in certain tissues, such as mouse embryonic
stem cells and hepatocytes (35). In our experiments, SR9009
treatment only affects Th17 differentiation in WT T cells, not
REV-ERBα/β double knockout T cells (Fig. 5 D and E), sug-
gesting that SR9009s inhibitory effects on Th17 cells is REV-
ERB dependent.
A concerted effort has been made to identify RORα/γ antag-
onists for treatment of Th17-related autoimmune diseases (5–8).
In fact, a recent clinical trial on an RORγ antagonist showed
encouraging results in psoriasis patients (36). In addition to Th17
cells, RORγt is also highly expressed in developing T cells in the
thymus. A recent report showed that RORγ antagonist treat-
ment leads to DP thymocyte apoptosis and reshapes the T cell
repertoire by skewing TCRα rearrangement (9). Although lim-


































































































Fig. 4. REV-ERBα deficiency impairs Th17 cell differentiation. (A) CD4+
T cells from REV-ERBαfl/fl/βfl/fl control and CD4Cre REV-ERBαfl/fl/βfl/fl mice were
activated under Th17 polarizing condition. After 3 d of culturing, IL-17A
production was analyzed by flow cytometry. FACS plots shown were rep-
resentative of 3 independent experiments. (B and C) REV-ERBαfl/fl/βfl/fl con-
trol and CD4Cre REV-ERBαfl/fl/βfl/fl mice were immunized with MOG/CFA to
induce EAE. (B) EAE disease progression scores. (C) IL-17A and IFN-γ pro-
duction in the CNS infiltrating CD4 T cell population at endpoint. Data
represents mean ± SEM. Statistical analyses were performed using unpaired
2-tailed Student’s t test or 2-way ANOVA for EAE disease scores (*P < 0.05,
****P < 0.0001).



































































































































































































































































































Fig. 5. REV-ERB agonist SR9009 inhibits Th17 differentiation and suppresses EAE. (A and B) Mouse CD4+ T cells were activated under Th1, Th17, and iTreg
polarizing conditions and treated with DMSO or SR9009. IFN-γ, IL-17A, and Foxp3 expression in Th1, Th17, and iTreg cells, respectively, were analyzed by flow
cytometry (n = 3). (C) IFN-γ and IL-17A production in human Th1 and Th17 polarized cells treated with either DMSO or SR9009. (D and E) CD4+ T cells from
REV-ERBαfl/fl/βfl/fl control and CD4Cre REV-ERBαfl/fl/βfl/fl mice were activated under Th17 polarizing condition and treated with DMSO or SR9009. IL-17A ex-
pression in Th17 cells was analyzed by flow cytometry (n = 5). (F) ChIP-qPCR to detect enhanced NCoR recruitment to the Il17a locus in response to SR9009. (G)
EAE disease progression of C57/BL6 mice that were immunized with MOG/CFA and treated with vehicle control or SR9009 via i.p. injections starting on day 7
after immunization (n = 5–6 per group). (H) IL-17A and IFN-γ production in the CNS infiltrating CD4 T cell population at endpoint. (I) EAE disease progression
of SJL mice immunized with PLP/CFA and treated with vehicle control or SR9009 daily starting at the beginning of the relapsing phase of EAE as indicated by
the arrow (n = 9 to 10 per group). (J) IL-17A and IFN-γ production in the CNS infiltrating CD4 T cell population at endpoint. Data represents mean ± SEM.
Statistical analyses were performed using 2-way ANOVA for EAE clinical score analysis and 2-tailed unpaired Student’s t test for other analysis, comparing the
indicated groups (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001).
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in some autoimmune disease settings, its long-term effect could
also increase the risk to cancer and certain infections. In contrast
to RORγt, the low expression levels of REV-ERBα and REV-
ERBβ in thymocytes and our own results (SI Appendix, Fig. S4)
suggest that REV-ERB agonists will not likely have the same im-
pact on thymocytes and the T cell repertoire as RORγ antagonists
(37). Therefore, a strategy of targeting REV-ERB alone or in
combination with RORγ may provide a unique advantage in de-
veloping treatments for Th17 cell-mediated autoimmune diseases.
Materials and Methods
Mice. Rosa-M2rtTA, TRE-REV-ERBα, and 2D2 transgenic mice were purchased
from Jackson Laboratory. The 3 transgenic lines were crossed to generate
Rosa-M2rtTAxTRE-RVBx2D2 triple transgenic mice. REV-ERBαfl/fl/βfl/fl mice
were generated previously (14). CD4Cre transgenic, C57BL/6, SJL/J, and
Ly5.1+ congenic mice were purchased from the Jackson Laboratory. All mice
were maintained in the Salk Institute specific pathogen free (SPF) animal
facility in accordance with the protocols approved by the Institutional
Animal Care and Use Committee (IACUC) at the Salk Institute.
Reverse Transcription and Quantitative PCR. Total RNA was isolated from CD4
T cells using TRIzol reagent (Life Technologies). cDNA was synthesized with
iScript Reverse Transcription Supermix for RT-qPCR (Bio-Rad), followed by
qPCR using SYBR Green PCR Master Mix (Applied Biosystems). Quantitative
PCR was performed on an Applied Biosystems ViiA 7 Real-Time PCR System
with gene specific primers listed in SI Appendix, Table S1.
Retroviral Transduction.HEK 293T cells were transfected via FuGENE6 reagent
(Promega), which contained 0.8 μg of pCL-Eco retroviral packaging plasmid
and 1.2 μg of expression plasmid. pCL-Eco was a gift from Inder Verma (Salk
Institute, La Jolla, CA) (38). Viral supernatant was harvested 48 and 72 h
after transfection. CD4+ T cells were cultured in Th17 polarizing condition
and retroviral transduction was performed 24 and 48 h after activation by
incubating cells with viral supernatant in the presence of polybrene (4 μg/mL;
Millipore) and centrifuged at 2,500 rpm for 90 min at 32 °C.
ChIP. Naive CD4+ T cells were activated and polarized in Th17 condition for
3 d for ChIP experiments as described previously (14). Mouse IgG control
antibody was purchased from Santa Cruz Biotechnology. RORγt ChIP was
performed with a combination of antibodies from BioLegend and Santa
Cruz Biotechnologies. REV-ERBα antibody was generated as previously de-
scribed (14). NCoR1 antibody was purchased from Cell Signaling. Primers
spanning the regulatory regions of Il17a, Cry1, and Gmpr are described in SI
Appendix, Table S2.
ChIP-Seq and Data Analysis. ChIP-seq libraries were constructed and sequenced
as described previously (14). Reads were aligned against the mouse mm9
reference genome using the Bowtie2 aligner with standard parameters
that allow up to 2 mismatches in the read. Peak calling, motif analyses, and
other data analysis were performed using HOMER, a software suite for ChIP-
seq analysis as described previously (14). Visualization of ChIP-Seq results
was achieved by uploading custom tracks onto the University of California,
Santa Cruz (UCSC) genome browser. ChIP-seq data can be accessed in the
National Center for Biotechnology Information (NCBI) GEO database under
the accession no. GSE72271.
RNA-Seq and Data Analysis. RNA-seq libraries were prepared from 100 ng of
total RNA (TrueSeq v2, Illumina) and single-ended sequencingwas performed
on the Illumina HiSeq 2500. Read alignment and junction finding was ac-
complished using STAR (39) and differential gene expression with Cuffdiff 2
(40). Student’s t test was performed to generate a list of differentially
expressed genes (P < 0.05), which was then run through KEGG pathway
analysis on DAVID (41, 42) to examine enriched functional groups. Heatmaps
were generated on Matrix2png (43). RNA-seq data can be accessed in the
NCBI Sequence Read Archive under accession no. SRP062715.
EAE Models. For active EAE, mice were immunized s.c. with 200 ng of MOG
(35–55) peptide (BL6 mice) or PLP (139–151) peptide (SJL mice) in CFA and
received 200 ng of Pertussis toxin intraperitoneally on days 0 and 2. Mice
were monitored daily for disease progression. At the end point, the brain
and spinal cord were harvested for histology and immune cell profiling. For
passive EAE, CD4 T cells from Rosa-M2rtTAxTRE-RVBx2D2 mice were acti-
vated under Th17 condition for 3 d, then restimulated overnight in the
presence of IL-18 (20 ng/mL; Fisher Scientific). Two to 3 million T cells were
adoptively transferred into WT recipient mice, which were given normal
water or Doxycycline water to induce REV-ERBα expression. EAE disease
progression was monitored as in the active EAE model.
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